Posted by Michael Wonder on 11 Mar 2021
EMA starts rolling review of Eli Lilly antibodies bamlanivimab and etesemivab for COVID-19
11 March 2021 - EMA’s CHMP has started a ‘rolling review’ of data on the antibodies bamlanivimab and etesemivab which are being developed by Eli Lilly to be used in combination for the treatment of COVID-19.
The review will also look at bamlanivimab used alone.
